期刊文献+

离子交联法制备聚唾液酸/壳聚糖纳米粒 被引量:1

Preparation of polysialic acid /chitosan nanoparticles via ionic gelation
下载PDF
导出
摘要 以聚唾液酸和壳聚糖为原料,多聚磷酸钠为交联剂,采用离子交联法制备聚唾液酸/壳聚糖纳米粒。结果表明:当聚唾液酸质量浓度为1.25 mg/mL,壳聚糖质量浓度为1.00 mg/mL,壳聚糖与聚唾液酸质量比为2∶1,多聚磷酸钠质量浓度为0.15 mg/mL,滴加速度为1滴/s时,所制备的聚唾液酸/壳聚糖纳米粒粒径最小,平均粒径为217.2 nm,纳米粒粒径分散指数为0.236。以牛血清白蛋白(BSA)为模型药物,包封率为(44.95±1.22)%,载BSA率为(28.90±0.78)%。离子交联法制备聚唾液酸/壳聚糖纳米粒操作简单快捷,不使用有机溶剂,所得纳米粒粒径较小,有望成为蛋白类药物的载体。 Polysialic acid/chitosan nanoparticles are developed via ionic gelation of two polysaccharide-based molecules,negatively charged polysialic acid and positively charged chitosan.Sodium tripolyphosphate is added as crosslinking agent.The minimum nanoparticle size can be achieved under the following conditions:1.25 mg/mL of polysialic acid,1.00 mg/mL of chitosan,2:1 mass ratio of chitosan to polysialic acid,0.15 mg/mL of tripolyphosphate and 1 drop/s of drop acceleration.The average size of the nanoparticle is 217.2 nm with a particle size distribution of 0.236.Using bovine serum albumin as a model drug,the loading efficiency and loading capacity are 44.95% and 28.90%,respectively.Preparation of polysialic acid/chitosan nanoparticles via ionic gelation is simple,quick and free of organic solvent.Such kind of small size polysialic acid/chitosan nanoparticle is a potential vehicle for the delivery of drug proteins.
出处 《现代化工》 CAS CSCD 北大核心 2014年第6期97-100,102,共5页 Modern Chemical Industry
基金 江苏省自然科学基金(BK2011158)
关键词 聚唾液酸 壳聚糖 纳米粒 牛血清白蛋白 polysialic acid chitosan nanoparticle bovine serum albumin
  • 相关文献

参考文献17

  • 1Zhang N, Bader R A. Synthesis and characterization of polysialic acid-N-trimethyl chitosan nanoparticles for drug delivery [ J ]. Nano LIFE ,2012,2 (03) : 1241003.
  • 2Krieg A, Weber C, Hoogenboom R, et al. Block copolymers of poly (2-oxazoline) s and poly(meth)acrylates :A crossover between cat- ionic ring-opening polymerization (CROP) and reversible addition- fragmentation chain transfer (RAIq') [J ]. ACS Macro Letters, 2012,1 (6) :776 -779.
  • 3Gregoriadis G, Jain S, Papaioannou I,et al. Improving the therapeu- tic efficacy of peptides and proteins:A role for polysialic acids [ J]. International Journal of Pharmaceuties,2005,300 ( 1 ) : 125 - 130.
  • 4Bergfeld A K, Claus H, Vogel U, et al. Biochemical characterization of thepolysialic acid-specific O-acetyhransferase NeuO of Escherich- ia eoli K1 [ J] . Journal of Biological Chemistry, 2007,282 ( 30 ) : 22217 - 22227.
  • 5Gregoriadis G, McCormack B, Wang Z, et al. Polysialic acids : Po- tential in drug delivery [ J ]. FEBS Letters, 1993,315 ( 3 ) : 271 - 276.
  • 6Mtihlenhoff M, Eckhardt M, Gerardy-Schahn R. Polysialic acid : Three-dimensional structure, biosynthesis and function [ J ]. Current Opinion in Structural Biology, 1998,8 (5) :558 - 564.
  • 7Fernandes A, Gregoriadis G. Synthesis, characterization and proper- ties of sialylated catalase [ J ]. Bioehimiea et Biophysica Acta, 1996,1293 ( 1 ) :90 -96.
  • 8Fernandes A, Gregoriadis G. Polysialy|ated asparaginase: Prepara- tion, activity and pharmacokineties [ J]. Biochimica et Biophysica Acta, 1997,1341 ( 1 ) :26 - 34.
  • 9Femandes A, Gregoriadis G. The effect of polysialylation on the im- munogcnicity and antigenicity of asparaginase: Implication in its phannacokinetics [ J ]. International Journal of Pharmaceutcs, 2001,217( 1 ) :215 -224.
  • 10Jain S, Hreczuk-Hirst D tt, McCormack B ,et al. Polysialylated insu- lin:Synthesis,characterization and biological activity in vivo [ J ]. Biochimica et Biophysica Aeta,2003,1622 ( 1 ) :42 - 49.

同被引文献7

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部